Steroid 5 alpha-reductase 3 (SRD5A3) promotes tumor growth and predicts poor survival of human hepatocellular carcinoma (HCC)

Qicong Mai¹*, Dafeng Sheng²*, Chengcong Chen³*, Qing Gou¹, Meng Chen¹, Xiaoting Huang³, Heng Yin⁴, Xiaoming Chen¹, Zide Chen¹,⁵

¹Department of Interventional Radiology, Cancer Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong, China
²PET/CT Center, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-Sen University, Shantou 515041, Guangdong, China
³Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, Guangdong, China
⁴Department of Medical Biotechnology, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong, China
⁵The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, Guangdong, China

*Equal contribution

Correspondence to: Zide Chen, Xiaoming Chen; email: doctorzidechen@qq.com, https://orcid.org/0000-0003-0483-0274; chenxiaoming@gdph.org.cn

Keywords: steroid 5 alpha-reductase 3, hepatocellular carcinoma, proliferation, bioinformatics analysis, clinical significance

ABSTRACT

Steroid 5 alpha-reductase 3 (SRD5A3) is an important molecule in glycosylation metabolism and steroid hormone formation. It is differentially expressed in human fetal liver, endometrial cancer and prostate cancer; however, its prognostic value and biological function in hepatocellular carcinoma (HCC) remain unclear. Here, bioinformatics analysis was employed to explore the expression and prognostic significance of SRD5A3 in various cancers including HCC. Additionally, clinical specimens of HCC were applied to analyze the expression of SRD5A3. SRD5A3-underexpressed HCC cell lines were established to test the effect of SRD5A3 on cell proliferation in in vitro and in vivo. We found that the elevated expression of SRD5A3 was common in many cancers with poor prognosis. Moreover, public datasets and our specimens revealed that SRD5A3 was also upregulated in HCC tissues and associated with clinical stage and patient’s gender. Kaplan-Meier survival analysis showed that higher SRD5A3 level predicted poor overall survival, progression-free survival, relapse-free survival and disease specific survival in HCC patients. Further experiments showed that the lack of SRD5A3 inhibited the growth of HCC. Collectively, these findings indicate that SRD5A3 functions as an oncogene and might serve as a potential biomarker for prognosis and a therapeutic target for HCC.

INTRODUCTION

According to the Global Cancer Statistics in 2018, liver cancer was the sixth most common and the fourth leading malignant tumor in the world [1]. About 841,000 new liver cancers and 782,000 liver cancer-related deaths occur annually [1]. Clinically, 75%-85% of primary liver cancers are pathologically diagnosed as...
hepatocellular carcinoma (HCC), which is considered to be induced by risk factors such as viral hepatitis B and C, alcohol, cirrhosis, fatty liver disease, diabetes, aflatoxin and aristolochic acid [1, 2]. Although radical surgery (such as hepatectomy, local ablation and liver transplantation) and palliative treatment (such as transarterial chemoembolization (TACE), molecular targeted therapy, and immunotherapy) are commonly used to treat patients with HCC, HCC metastasis and relapse are still prone to occur and eventually lead to an unsatisfactory prognosis [2–4]. The malignant behaviors of HCC are most likely due to the accumulation of changes in the genome and multifaceted molecular pathways [5, 6]. Therefore, the identification of molecules essential for the proliferation and progression of HCC is important, not only for predicting prognosis and targeted therapy, but also for a comprehensive understanding of molecular biological mechanisms involved in the development of HCC.

Steroid 5 alpha-reductase 3 (SRD5A3) is a protein-coding gene belonging to the steroid 5-alpha reductase family, which also includes steroid 5 alpha-reductase 1 (SRD5A1) and steroid 5 alpha-reductase 2 (SRD5A2) [7, 8]. These steroid 5-alpha reductase enzymes regulate the production of steroid hormones and male sexual development by catalyzing the conversion of testosterone into the most potent natural androgen 5 alpha-dihydrotestosterone (DHT) [9, 10]. Additionally, they are also involved in the activation of the androgen-receptor (AR) pathway [9, 10]. Among them, SRD5A1 and SRD5A2 were reported to be highly expressed in human liver, and the protein level of SRD5A1 increased with the severity of nonalcoholic fatty liver disease (NAFLD) [11]. Moreover, the absence of SRD5A1 accelerated the progression of hepatic steatosis but protected against the development of NAFLD-related HCC [11]. Further research showed that the expression of SRD5A1 can be elevated by hepatocyte growth factor (HGF) through up-regulating the transcription factor Egr-1 [12]. In addition, SRD5A2 was found to be aberrantly methylated in HCC tissues (20 cases) but not in any corresponding non-HCC liver tissues (20 cases), and served as a biomarker for early diagnosis of HCC [13, 14]. All these studies indicated that SRD5A1 and SRD5A2 are involved in the carcinogenesis and development of HCC. As an isoenzyme of SRD5A1 and SRD5A2, the discovery of SRD5A3 was relatively late [15]. Recent studies demonstrated that SRD5A3 was overexpressed in human fetal liver, endometrial cancer, hormone-refractory prostate cancer as well as metastatic prostate cancer [10, 15–17]. However, SRD5A3 expression, its impact on the prognosis of HCC patients, and its role in the biological behavior of HCC have not yet been elucidated.

In the current study, SRD5A3 expression in different cancers including HCC was analyzed by bioinformatics, and further verified with clinical specimens of HCC tumor (HCC) and corresponding adjacent non-HCC liver (peri-HCC). Then, the correlation between SRD5A3 expression, clinical progression of HCC and survival prognosis of different cancer patients were studied. Furthermore, we examined the biological effects of SRD5A3 on HCC growth through in vitro and in vivo experiments. Finally, the molecular mechanisms behind these biological functions were explored.

RESULTS

SRD5A3 is highly expressed in various tumor tissues including HCC

We first employed the UALCAN web portal to explore the general expression of SRD5A3 in different cancers (Figure 1). Various cancers including HCC showed moderate to strong expression of SRD5A3 compared to their corresponding normal tissues. In order to verify whether this high expression of SRD5A3 in HCC tumor tissues is a common phenomenon, seven HCC datasets including GSE22058, GSE25097, GSE36376, GSE63898, GSE64041, TCGA(LIHC), and GSE54236 were analyzed (Figure 2). Bioinformatics analysis of these datasets revealed that the expression of SRD5A3 in HCC tissues was generally higher than that in non-HCC liver tissues (Figure 2A–2F) and corresponding adjacent liver tissues (Figure 2G–2I). Additionally, we performed quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and Western blot analyses to verify this speculation again. Our data displayed that the mRNA and protein expression of SRD5A3 were significantly increased in the tumor tissues of 36 HCC patients compared with the matched adjacent non-HCC liver tissues (Figure 3A–3C), which was consistent with the results in public datasets. Immunohistochemistry (IHC) staining showed that SRD5A3 protein was predominantly located in the cytoplasm of HCC and liver cells (Figure 3D).

Up-regulation of SRD5A3 is associated with the tumor progression of HCC

Next, the association between SRD5A3 expression and corresponding clinicopathological characteristics was evaluated. We found that the expression of SRD5A3 had a significant correlation with the clinical stage of HCC (P = 0.0222, F = 3.247, Figure 4A). Moreover, as vascular invasion intensified, the average expression of SRD5A3 seemed to increase; however, no significant statistical difference was detected among them (Figure 4B). Interestingly, we found that the expression of SRD5A3 was also associated with the patient's gender (Figure 4C). The average expression of SRD5A3 in female HCC
patients tended to be higher than that of male HCC patients (Figure 4C).

**Up-regulation of SRD5A3 is associated with the prognosis of cancers including HCC**

To confirm the correlation between the SRD5A3 expression and the prognosis of HCCs, survival rates between the high and low SRD5A3 level groups were compared. We performed these analyses on the Kaplan–Meier plotter survival analysis platform, and found that HCC patients in the high SRD5A3 expression group had poorer overall survival (OS, HR = 1.91 (1.34 – 2.73), log-rank test P = 0.00029), relapse-free survival (RFS, HR = 1.59 (1.14 – 2.22), log-rank test P = 0.0055), progression-free survival (PFS, HR = 1.61 (1.20 – 2.17), log-rank test P = 0.0015) and disease specific survival (DSS, HR = 2.13 (1.35 – 3.39), log-rank test P = 0.00098) rates than that in the low SRD5A3 expression group (Figure 5A–5D). These were consistent with the data of HCC in the Human Protein Atlas database (Figure 5E), which again indicated that up-regulation of SRD5A3 expression predicts poor prognosis of HCC.

Moreover, we also explored the prognostic significance of SRD5A3 in other cancers, and found that the high expression of SRD5A3 was associated with the poor OS rates of skin cutaneous melanoma (SKCM, P = 0.00034), kidney renal clear cell carcinoma (KIRC, P = 0.023), kidney renal papillary cell carcinoma (KIRP, P = 0.018), uveal melanoma (UVM, P = 0.0071), brain lower grade glioma (LGG, P = 0.037), breast invasive

---

**Figure 1. The expression of SRD5A3 in various carcinomas.** Transcriptional expression of SRD5A3 in 24 types of cancer (the UALCAN web portal).
canceroma (BRCA, P = 0.041), thyroid carcinoma (THCA, P = 0.036), and glioblastoma multiforme (GBM, P = 0.048) (Figure 6A–6H). These results suggested that high expression of SRD5A3 may be a common unfavorable prognostic factor for many different types of cancer.

Knockdown of SRD5A3 suppresses the growth of HCC in vitro and in vivo

To investigate the potential biological function of SRD5A3 in HCC tumorigenesis, we knocked down the expression level of SRD5A3 in HCC cell lines by infect-
ing them with SRD5A3 shRNA (sh-SRD5A3) lentivirus or control vector (sh-NC). The knockdown efficiency was evaluated by Western blot and qRT-PCR analyses (Figure 7A–7E). Colony formation and cell viability assays were applied to reflect the proliferation inhibitory ability in the HCC cells lacking SRD5A3. As shown in Figure 7F–7J, the colony formation rate and the cell viability of HCC cell lines infected with sh-SRD5A3

Figure 3. qRT-PCR, Western blot and IHC measurements of SRD5A3 in HCC and peri-HCC tissues. (A) The mRNA expression of SRD5A3 in 36 pairs of HCC and peri-HCC tissues was measured by qRT-PCR analysis. The SRD5A3 mRNA levels of peri-HCC tissues were normalized as ‘1’. (B, C) The protein level of SRD5A3 in 7 pairs of HCC and peri-HCC tissues was analyzed by Western blot. (D) The location of SRD5A3 protein was detected by IHC staining. T, HCC tumor tissue; N, peri-HCC tumor tissue.

Figure 4. The expression of SRD5A3 is correlated with the clinical stage and the gender of HCC patients. In the TCGA(LIHC) dataset, the correlation between (A) clinical stage, (B) vascular invasion, (C) gender, and SRD5A3 expression was analyzed in HCC patients with clinical data. LIHC, liver hepatocellular carcinoma (HCC).
were lower than that of cells infected with sh-NC. Furthermore, we inoculated HCC cells infected with sh-SRD5A3 or sh-NC in immunodeficient mice subcutaneously. The tumor growth curve, image and weight suggested that the down-regulation of SRD5A3 inhibited the growth of HCC (Figure 8A–8E).

**Molecular mechanisms behind the cellular function of SRD5A3**

Finally, the potential molecular mechanisms behind the effects of SRD5A3 in HCC were predicted. The GeneMANIA and STRING databases showed that SRD5A3 might interact with TECRL, SLC25A51, SRD5A1, SRD5A2, TECR, NUDT15, SLC25A25, SLC25A24, ADK, MSH4, SPTSSA, DNM3, C4BPA, CYP27B1, MFSD6, JTB, PON2, TMEM167A, TEFM, POLDIP2, SYPI7A1, HSD17B3, DOLK, AKR1C3, SRD5A1 and etc. (Figure 9A, 9B). Moreover, the miRNA Cancer MAP web portal predicted several more reliable microRNAs upstream of SRD5A3 based on the TCGA (LIHC) dataset. These microRNAs included miR-125b-2-3p, miR-130a-3p, miR-126-5p, miR-450b-5p, miR-186-5p, miR-139-5p and miR-342-3p (Figure 9C). And the UALCAN web portal showed that SRD5A3 was hypomethylated in HCC tissues (Figure 9D), suggesting that the high level of SRD5A3 in HCC might be related to the hypomethylation status. Moreover, the GEPIA2 web portal showed that SRD5A3 was positively correlated with some genes such as PPIAP22 (R=0.56, P<0.05), EIF3K (R=0.56, P<0.05), KIAA1522 (R=0.54, P<0.05), MYL6 (R=0.54, P<0.05), PPIA (R=0.53, P<0.05), MRP512 (R=0.53, P<0.05), SUMF2

---

**Figure 5.** The association of the SRD5A3 expression and the prognosis of HCC. (A) Overall survival (OS), (B) relapse-free survival (RFS), (C) progression-free survival (PFS) and (D) disease specific survival (DSS) curve based on high and low expression levels of SRD5A3 from the Kaplan–Meier plotter survival analysis platform. (E) Prognostic significance of SRD5A3 expression in HCC in the Human Protein Atlas database. HR, hazard ratio.
(R=0.53, P<0.05), RRP36 (R=0.53, P<0.05), ORMDL2 (R=0.53, P<0.05) and etc. (Table 1). Some of them were genes related to the cell cycle, including CDK5 (R=0.42, P<0.05), CDK4 (R=0.41, P<0.05), CDK7 (R=0.40, P<0.05), CDKAL1 (R=0.40, P<0.05), CCNB1 (R=0.36, P<0.05), CDK1 (R=0.35, P<0.05) and PLK1 (R=0.32, P<0.05) (Figure 9E–9K and Table 1). Additionally, AR expression was found to have a negative correlation with SRD5A3 (Figure 9L and Table 1).

**DISCUSSION**

HCC is one of the most aggressive and enigmatic malignant tumors worldwide, causing millions of deaths per year [1]. The carcinogenesis and development of HCC are generally considered to be related to a variety of factors, such as hepatitis B or C virus infection, cirrhosis, fatty liver disease, diabetes, alcohol, aflatoxin, aristolochic acid and so on [2]. Although some exact genes and pathways driving the pathogenesis of HCC have been discovered, many others have not yet been detected and explored [18, 19].

In the human genome, SRD5A3 is located on chromosome 4 and is about 36 kDa in length. It is a member of the steroid 5-alpha reductase family which is considered to play an important role in male sexual development [8–10]. Here, we found SRD5A3 was generally upregulated in HCC as well as many other malignant tumor tissues. As is well-known, HCC is more prevalent in males than in females, with a gender-specific ratio of 2:1 to 8:1 [20, 21]. Males develop HCC faster and more severe than females [20]. The reason for this gender disparity is related to sex hormones, but it is not well understood yet [22].

Recent studies indicated that the activation of androgen-AR pathway could accelerate the pathogenesis and progression of HCC [22–24]. The expression of AR was discovered to be elevated in HCC tissues compared to that in non-HCC liver tissues [22–24]. And the over-expression of AR promoted hepatocarcinogenesis and cell growth of HCC via promoting DNA damage and reactive oxidative stress, as well as suppressing DNA damage sensing and repairing system mediated by p53 [23].

**Figure 6. The expression of SRD5A3 has prognostic value in various malignant cancers.** In the UALCAN website portal, the effect of high and low expression levels of SRD5A3 on the overall survival of (A) skin cutaneous melanoma (SKCM), (B) kidney renal clear cell carcinoma (KIRC), (C) kidney renal papillary cell carcinoma (KIRP), (D) uveal melanoma (UVM), (E) brain lower grade glioma (LGG), (F) breast invasive carcinoma (BRCA), (G) thyroid carcinoma (THCA) and (H) glioblastoma multiforme (GBM) cancer patients.
addition, mouse liver lacking AR was found to develop later and less tumorigenesis than the normal liver [23]. These results suggested that targeting androgen-AR signaling was a potential strategy for HCC therapy [22–24].

The maintenance of androgen-AR activation pathway requires steroid 5-alpha reductase enzymes (SRD5A1, SRD5A2, and SRD5A3), and this signaling pathway also regulates the mRNA expression of these steroid 5-alpha

Figure 7. SRD5A3 inhibition suppresses cell proliferation of HCC in vitro. SMMC-7721 and QGY-7703 cell lines were infected with sh-SRD5A3 or sh-NC lentivirus. The knockdown efficiency of SRD5A3 was confirmed by (A–C) Western blot and (D, E) qRT-PCR analyses. (F–H) Colony formation assays were performed and analyzed. (I, J) CCK-8 assays were conducted to measure cell viability (two-way ANOVA analysis). NC, negative control. *, P value < 0.05.
reductase enzymes [8–10]. Thus, steroid 5-alpha reductase enzymes, such as SRD5A3, may be related to the gender disparity in patients with HCC and affect the progression of HCC. Previously, SRD5A3 was confirmed to be overexpressed in human fetal liver [17]. The gender differences existed in the expression of SRD5A3 in fetal liver (higher in males) [17]. Interestingly, in the present study, we also found a significant difference between the expression of SRD5A3 in male and female HCCs, while the SRD5A3 expression was negatively correlated with the AR expression. These data hinted SRD5A3 might be involved in the regulation of androgen-AR signaling. However, unlike expected, the SRD5A3 expression in female HCC tissues was higher than that in males. The reason was not clear and needs further investigation. Moreover, our results showed that SRD5A3 was a malignant aggressive molecule and a poor prognostic factor in HCC patients. The suppression of SRD5A3 inhibited the HCC growth in vitro and in vivo, suggesting that SRD5A3 may also be a novel potential target for HCC therapy.

To investigate the mechanisms by which SRD5A1 interferes with HCC proliferation, we resorted to the interaction databases. Through the interaction analysis, multiple protein-coding genes and microRNAs were suggested to be related to SRD5A3. Among them, SRD5A1 [11, 12], SRD5A2 [13, 14], adenosine kinase (ADK) [25], Dynamin 3 (DNM3) [26], miR-125b-2-3p [27], miR-130a-3p [28], miR-126-5p [29], miR-450b-5p [30], miR-186-5p [31], miR-139-5p [32] and miR-342-3p [33] have been reported to influence the growth, invasion, metastasis or drug resistance of HCC. Furthermore, correlation exploration in the present study hinted that SRD5A3, together with other members of steroid 5-alpha reductase enzymes (SRD5A1 and SRD5A2), may also be correlated with other molecules, such as PPIAP22, EIF3K, KIAA1522 and etc. Moreover, the effect of SRD5A3 on HCC growth may involve the regulation of the cell cycle through CDK5, CDK4, CDK7, CDKAL1, CCNB1, CDK1, and PLK1.

![Figure 8. Down-regulation of SRD5A3 suppresses HCC cell growth in vivo.](image)

(A, B) Growth curve of the xenograft tumors (two-way ANOVA analysis). (C, D) Images and weight of xenograft tumors in sh-SRD5A3 and sh-NC groups (unpaired t-test). Three mice per group. NC, negative control. Error bar, mean with standard deviation. *, P value < 0.05.
Figure 9. Potential molecular mechanisms behind the effects of SRD5A3. (A, B) Protein-protein interaction network between SRD5A3 and other protein-coding genes from the GeneMANIA and STRING databases. (C) Upstream microRNA of SRD5A3 from the miRNAcancerMAP web-portal. (D) Methylation level of SRD5A3 from the UALCAN web portal. (E–L) Correlation analysis between CDK5, CDK4, CDK7, CDKAL1, CCNB1, CDK1, PLK1, AR and SRD5A3 in the GEPIA2 website portal. R, correlation coefficient.
Table 1. Correlation between the expression of SRD5A3 and other genes.

| Gene symbol | Gene identification | Pearson's correlation coefficient (R value) | P value |
|-------------|---------------------|---------------------------------------------|---------|
| PPIAP22     | ENSG00000198618.5   | 0.56                                        | <0.05   |
| EIF3K       | ENSG00000178982.9   | 0.56                                        | <0.05   |
| KIAA1522    | ENSG00000162522.10  | 0.54                                        | <0.05   |
| MYL6        | ENSG00000092841.18  | 0.54                                        | <0.05   |
| PPIA        | ENSG00000196262.13  | 0.53                                        | <0.05   |
| MRPS12      | ENSG00000128626.11  | 0.53                                        | <0.05   |
| SUMF2       | ENSG00000129103.17  | 0.53                                        | <0.05   |
| RRP36       | ENSG00000124541.6   | 0.53                                        | <0.05   |
| ORMDL2      | ENSG00000123353.9   | 0.53                                        | <0.05   |
| APOA1BP     | ENSG00000163382.11  | 0.52                                        | <0.05   |
| SLC35E1     | ENSG00000127526.13  | 0.52                                        | <0.05   |
| H2AFV       | ENSG00000105968.18  | 0.52                                        | <0.05   |
| SLC35B2     | ENSG00000157593.16  | 0.52                                        | <0.05   |
| COX5A       | ENSG00000178741.11  | 0.52                                        | <0.05   |
| UQCR10      | ENSG00000184076.12  | 0.52                                        | <0.05   |
| LSM2        | ENSG00000204392.10  | 0.52                                        | <0.05   |
| MEA1        | ENSG00000124733.3   | 0.51                                        | <0.05   |
| ATP5O       | ENSG00000241837.6   | 0.51                                        | <0.05   |
| NOA1        | ENSG00000084092.6   | 0.51                                        | <0.05   |
| CHMP3       | ENSG00000115561.14  | 0.51                                        | <0.05   |
| RPN2        | ENSG00000118705.16  | 0.51                                        | <0.05   |
| YWHAB       | ENSG00000166913.12  | 0.51                                        | <0.05   |
| BOLA3       | ENSG00000163170.11  | 0.51                                        | <0.05   |
| OST4        | ENSG00000228474.5   | 0.51                                        | <0.05   |
| UFC1        | ENSG00000143222.11  | 0.51                                        | <0.05   |
| ATG7        | ENSG00000197548.12  | 0.48                                        | <0.05   |
| BAX         | ENSG00000087088.19  | 0.47                                        | <0.05   |
| BAK1        | ENSG00000030110.12  | 0.47                                        | <0.05   |
| CLOCK       | ENSG00000134852.14  | 0.46                                        | <0.05   |
| CBX3        | ENSG00000122565.18  | 0.46                                        | <0.05   |
| CDK5        | ENSG00000164885.12  | 0.42                                        | <0.05   |
| CDK4        | ENSG00000135446.16  | 0.41                                        | <0.05   |
| CDK7        | ENSG00000134058.10  | 0.4                                         | <0.05   |
| CDKAL1      | ENSG00000145996.11  | 0.4                                         | <0.05   |
| CCNB1       | ENSG00000134057     | 0.36                                        | <0.05   |
| CDK1        | ENSG00000170312     | 0.35                                        | <0.05   |
| PLK1        | ENSG00000166851     | 0.32                                        | <0.05   |
| AR          | ENSG00000169083     | -0.22                                       | <0.05   |

The statistics of these data are based on the GEPIA2 web portal.
Taken together, our bioinformatics analyses suggested that elevated SRD5A3 expression is associated with a depressing prognosis of various malignancies including HCC. The expression of SRD5A3 in female HCC tissues tends to be higher than that in males. Loss-of-function experiments indicated that SRD5A3 accelerates the development of HCC by promoting cell proliferation.

To the best of our knowledge, this is the first research to provide evidence of SRD5A3 as an oncogene by exploring its prognostic value, cellular function, and molecular mechanism in HCC. However, the sample size of HCC patients recruited from our affiliation was relatively small and the mechanism exploration was still only in the prediction stage. Therefore, further investigations are wanted in the follow-up studies.

MATERIALS AND METHODS

Bioinformatics analysis

SRD5A3 expression in various cancers and its relationship with tumor progression were analyzed via employing the UALCAN web portal (http://ualcan.path.uab.edu/index.html), the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/) and The Cancer Genome Atlas database (TCGA, https://cancergenome.nih.gov/). The impact of SRD5A3 expression on survival prognosis of different cancer patients was predicted by the Kaplan–Meier plotter survival analysis platform (https://kmplot.com/analysis/), Human Protein Atlas database (https://www.proteinatlas.org/) and UALCAN web portal. Methylation level of SRD5A3 was analyzed by UALCAN web portal. Potential interactions between SRD5A3 and other coding genes or microRNAs were predicted by using GeneMANIA (http://genemania.org/search/), STRING (https://string-db.org/cgi/input.pl), and miRNA Cancer MAP (http://cis.hku.hk/miRNA Cancer MAP/MAPQuest1.php) and GEPIA2(http://gepia2.cancer-pku.cn/) website portals.

Clinical specimens

HCC tumor (HCC) and adjacent non-HCC liver tissues (peri-HCC) were obtained from 36 patients who underwent hepatectomy after signing informed consent. The specimens were immediately stored in liquid nitrogen until analysis. The clinical data and pathological characteristics of these HCC patients were summarized in Supplementary Table 1. The application of HCC specimens was approved by the Ethics Committee of Guangdong Provincial People’s Hospital.

RNA isolation and qRT-PCR

Total RNA was extracted from HCC tumor tissues and corresponding adjacent non-HCC liver tissues following the instruction of TRIzol reagent (Cat. no. T9109, TaKaRa, USA). The reverse transcription of mRNA was performed by using PrimeScript RT Master Mix Kit (Cat. no. RR036A, TaKaRa, USA). The cDNA generated above was used as a template to detect the mRNA expression of SRD5A3 with TB Green™ Premix Ex Taq™ detection kit (Cat. no. RR420A, TaKaRa, USA). β-actin gene acts as an internal control. Primer sequences were as follows: SRD5A3 (forward primer: 5’-TTTAATCAGGCCCTGTCTGC-3’, reverse primer: 5’-GGGGTATAGAAATGGAATGGAGA-3’); β-actin (forward primer: AGCGAGCATCCCCAAAAGTT, reverse primer: GGGCACGAAGGCTCATCATT). These primers were synthesized by RuiBiotech (China). The relative expression of SRD5A3 mRNA level was computed according to the 2^-ΔΔCt method.

Western blot analysis

Total protein was extracted from specimens or cell lines using RIPA lysis buffer (Cat. no. #FD008, Fdbio Science, China) supplemented with protease inhibitor cocktail (Cat. no. #FD1001, Fdbio Science, China) and phosphatase inhibitor cocktail (Cat. no. #FD1002, Fdbio Science, China). The protein supernatant was collected after centrifuging at 14000 g and 4°C. Then, the concentration of the protein supernatant was quantified using bicinchoninic acid assay kit (Cat. no. #FD2001, Fdbio Science, China), and boiled at 100°C for 10 minutes. Equal amounts of protein from different samples were separated by polyacrylamide gel electrophoresis and transferred onto 0.45 μm nitrocellulose filter membranes (GE Healthcare, United States). Subsequently, the membranes were probed with primary antibodies against human SRD5A3 (Cat. no. #NB1-69612, Novus, United States) or β-actin (Cat. no. #4970, Cell Signaling Technology, United States) overnight at 4°C, followed by incubation with a secondary horseradish peroxidase (HRP)-conjugated antibody for 60 minutes at room temperature. Finally, protein blot images were detected using an enhanced chemiluminescence kit (Cat. no. #WBKLS0100, Millipore, United States), and were quantified by using ImageJ software (Ver. 1.46r; MD, United States).

Immunohistochemistry (IHC) staining

HCC tumor and adjacent non-HCC liver tissues embedded in paraffin were sectioned onto 3-μm-thick slices. After retrieving antigen by heating in citrate buffer (pH 6.0) and blocking endogenous peroxidase activity by H2O2, the slices were incubated with the primary
antibody against SRD5A3 (Cat. no. #HPA027006, Sigma, United States) at a concentration of 1:50 overnight. Then, the slices were incubated with a secondary HRP-conjugated antibody. Subsequently, the slices were stained with diaminobenzidine (DAB) and counterstained with hematoxylin. Finally, the staining images were captured.

**Cell culture**

Human HCC cell lines QGY-7703 and SMMC-7721 were obtained from the Guangzhou Jennio Biotech Co., Ltd. (GD, China). Cells were maintained in high glucose Dulbecco’s modified Eagle’s medium (DMEM, Gibco, MA, United States) supplemented with 10% fetal bovine serum (FBS, Gibco, MA, United States) at 37°C in 5% CO2 condition, and were routinely checked for mycoplasma contamination.

**Establishment of HCC cell lines with down-regulated SRD5A3**

A lentiviral SRD5A3 interference vector was obtained from Hanbio Biotechnology Co., Ltd. (Shanghai, China). The sequence of SRD5A3 and negative control (NC) shRNA were as follows: AAATAAACGAG AGTGGTACATT (sh-SRD5A3), TTCTCCGAACG TGTCACGT (sh-NC). Lentivirus production, viral infection and qRT-PCR were performed according to the manufacturer’s instructions. Positive and stable infectants were selected by puromycin.

**Colony formation**

Colony formation experiment was performed as previously described [34, 35]. In brief, 500 cells infected with sh-SRD5A3 or sh-NC were seeded in 6-well plates. After culturing in DMEM medium supplemented with 10% FBS for 7 to 14 days, the cell colonies were fixed with methanol for 2 minutes, then stained with crystal violet for 30 minutes at room temperature. After washing away excess dye, the number of cell colonies was counted by imageJ (Ver. 1.46r; MD, United States) software.

**Cell viability measurement**

3 × 103 cells were seeded per well in 96-well plate, then the CCK-8 (Dojindo, Japan) assay was performed every 24 hours for 4 consecutive days as previously described to measure cell viability [34, 36].

**Tumor xenograft experiments**

BALB/c female nude mice (four-week-old) were subcutaneously inoculated with 5×10⁶ HCC cells stably infected with sh-SRD5A3 or sh-NC. Tumor length and tumor width were measured every 3 days for a total of 18 days. The tumor volume was calculated as length × width²/2. The animal experiment was approved by the Animal Health and Ethics Committee. All procedures for this experiment were conducted in accordance with the guidelines for the care and use of laboratory animals.

**Statistical analysis**

All data were expressed as the mean ± standard deviation. Statistical comparisons were performed using unpaired or paired Student's t test in two-groups, or ANOVA (one-way or two-way) test among more than two groups. The OS, RFS, PFS and DSS survival curves of HCC patients were generated by Kaplan-Meier method, then analyzed via log-rank test. The analyses in this study were conducted through GraphPad Prism 6.0 software (United States). P value < 0.05 was defined as statistically significant.

**Abbreviations**

ADK: adenosine kinase; AR: androgen receptor; BRCA: breast invasive carcinoma; CCK-8: Cell counting Kit-8; DHT: dihydrotestosterone; DNMT3: Dynamin 3; DSS: disease specific survival; GEO: Gene Expression Omnibus; GBM: glioblastoma multiforme; HCC: hepatocellular carcinoma; HGF: hepatocyte growth factor; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LGG: brain lower grade glioma; NAFLD: nonalcoholic fatty liver disease; OS: overall survival; peri-HCC: corresponding adjacent non-HCC liver; PFS: progression-free survival; qRT-PCR: quantitative reverse-transcription polymerase chain reaction; RFS: relapse-free survival; sh-NC: control vector; sh-SRD5A3: SRD5A3 shRNA; SKCM: skin cutaneous melanoma; SRD5A1: steroid 5 alpha-reductase 1; SRD5A2: steroid 5 alpha-reductase 2; SRD5A3: steroid 5 alpha-reductase 3; TACE: transarterial chemoembolization; TCGA: The Cancer Genome Atlas; THCA: thyroid carcinoma; UVM: uveal melanoma.

**AUTHOR CONTRIBUTIONS**

Zide Chen and Xiaoming Chen designed the study. Qicong Mai, Dafeng Sheng and Chengcong Chen collected the required data from web portals and databases for bioinformatics analysis, and conducted the biological function experiments. Qicong Mai, Qing Gou, Meng Chen and Xiaoting Huang collected the clinical specimens and corresponding clinical information. Heng Yin re-checked the process of statistical analysis and provided technical consultation. The manuscript was
CONFLICTS OF INTEREST

All authors in this work declare no conflicts of interest.

FUNDING

This study was funded by the Wu Jieping Medical Foundation (grant numbers 320.6750.19088-96) and the China Postdoctoral Science Foundation (grant numbers 2019M663396 and 2020M672595).

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. https://doi.org/10.3322/caac.21492 PMID:30207593

2. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16:589–604. https://doi.org/10.1038/s41575-019-0186-y PMID:31439937

3. Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018; 48:598–609. https://doi.org/10.1111/apt.14913 PMID:30039640

4. Forner A, Da Fonseca LG, Díaz-González Á, Sanduzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep. 2019; 1:17–29. https://doi.org/10.1016/j.jhepr.2019.02.003 PMID:32039350

5. Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: an update. World J Gastroenterol. 2016; 22:9069–95. https://doi.org/10.3748/wjg.v22.i41.9069 PMID:27895396

6. Dhanasekararan R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy. Gastroenterology. 2019; 156:492–509. https://doi.org/10.1053/j.gastro.2018.11.001 PMID:30404026

7. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest. 1993; 92:903–10. https://doi.org/10.1172/JCI116665 PMID:7688765

8. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One. 2011; 6:e28840. https://doi.org/10.1371/journal.pone.0028840 PMID:22194926

9. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci USA. 1990; 87:3640–44. https://doi.org/10.1073/pnas.87.10.3640 PMID:2339109

10. Ateeq B, Vellaichamy A, Tomlins SA, Wang R, Cao Q, Lonigro RJ, Pienta KJ, Varambally S. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. Prostate. 2012; 72:1542–49. https://doi.org/10.1002/pros.22509 PMID:22415461

11. Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolau N, van Houten EL, Visser JA, Morgan SA, Laverty GG, Oprescu A, Hübscher SG, Newsome PN, Tomlinson JW. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013; 154:4536–47. https://doi.org/10.1210/en.2013-1592 PMID:24080367

12. Rui C, Li C, Xu W, Zhan Y, Li Y, Yang X. Involvement of Eg-1 in HGF-induced elevation of the human Salpha-R1 gene in human hepatocellular carcinoma cells. Biochem J. 2008; 411:379–86. https://doi.org/10.1042/BJ20071343 PMID:18215136

13. Moribe T, Iizuka N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, Hamamoto Y, Sakamoto K, Tamesa T, Oka M. Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search. Int J Oncol. 2008; 33:949–58. PMID:18949357

14. Tsunodemi R, Ogawa Y, Iizuka N, Sakamoto K, Tamesa T, Moribe T, Oka M. The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma. Int J Oncol. 2010; 36:205–12. PMID:19956849

15. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, Nakagawa H. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008; 99:81–86.
16. Wang ZH, Zhang YZ, Wang YS, Ma XX. Identification of novel cell glycolysis related gene signature predicting survival in patients with endometrial cancer. Cancer Cell Int. 2019; 19:296. https://doi.org/10.1186/s12935-019-1001-0 PMID:31807118
17. O'Shaughnessy PJ, Monteiro A, Bhattacharya S, Fraser MJ, Fowler PA. Steroidogenic enzyme expression in the human fetal liver and potential role in the endocrinology of pregnancy. Mol Hum Reprod. 2013; 19:177–87. https://doi.org/10.1093/molehr/gas059 PMID:23197595
18. Oggunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol. 2019; 25:2279–93. https://doi.org/10.3748/wjg.v25.i19.2279 PMID:31148900
19. Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers (Basel). 2020; 12:491. https://doi.org/10.3390/cancers12020491 PMID:32093152
20. Li Y, Li H, Spitsbergen JM, Gong Z. Males develop faster and more severe hepatocellular carcinoma than females in krasV12 transgenic zebrafish. Sci Rep. 2017; 7:41280. https://doi.org/10.1038/srep41280 PMID:28117409
21. Shi L, Feng Y, Lin H, Ma R, Cai X. Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med. 2014; 12:93. https://doi.org/10.1186/1479-5876-12-93 PMID:24708807
22. Zheng B, Zhu YJ, Wang HY, Chen L. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Sci China Life Sci. 2017; 60:575–84. https://doi.org/10.1007/s11427-016-9043-9 PMID:28547581
23. Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S, Chang C. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008; 135:947–55. https://doi.org/10.1053/j.gastro.2008.05.046 PMID:18639551
24. Ma WL, Lai HC, Yeh S, Cai X, Chang C. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. Endocr Relat Cancer. 2014; 21:R165–82. https://doi.org/10.1530/ERC-13-0283 PMID:24424503
25. Mori K, Hiraoka O, Ikeda M, Ariumi Y, Hiramoto A, Wataya Y, Kato N. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Hepatology. 2013; 58:1236–44. https://doi.org/10.1002/hep.26421 PMID:23532970
26. Zhang Z, Chen C, Guo W, Zheng S, Sun Z, Geng X. DNMT3 attenuates hepatocellular carcinoma growth by activating P53. Med Sci Monit. 2016; 22:197–205. https://doi.org/10.12659/msm.896545 PMID:26784388
27. Shi J, Ye G, Zhao G, Wang X, Ye C, Thammavong K, Xu J, Dong J. Coordinative control of G2/M phase of the cell cycle by non-coding RNAs in hepatocellular carcinoma. PeerJ. 2018; 6:e5787. https://doi.org/10.7717/peerj.5787
28. Liu Y, Li Y, Wang R, Qin S, Liu J, Su F, Yang Y, Zhao F, Wang Z, Wu Q. MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. J Exp Clin Cancer Res. 2016; 35:19. https://doi.org/10.1186/s13046-016-0296-0 PMID:26817584
29. Zhao Y, Ye L, Yu Y. MicroRNA-126-5p suppresses cell proliferation, invasion and migration by targeting EGFR in liver cancer. Clin Res Hepatol Gastroenterol. 2020. [Epub ahead of print]. https://doi.org/10.1016/j.clinre.2020.03.025 PMID:32409283
30. Li H, Shen S, Chen X, Ren Z, Li Z, Yu Z. miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway. Cancer Cell Int. 2019; 19:205. https://doi.org/10.1186/s12935-019-0923-x PMID:31388332
31. Shan Y, Li P. Long intergenic non-protein coding RNA 665 regulates viability, apoptosis, and autophagy via the MiR-186-5p/MAP4K3 axis in hepatocellular carcinoma. Yonsei Med J. 2019; 60:842–53. https://doi.org/10.3349/ymj.2019.60.9.842 PMID:31433582
32. Hua S, Lei L, Deng L, Weng X, Liu C, Qi X, Wang S, Zhang D, Zou X, Cao C, Liu L, Wu D. miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1. Oncogene. 2018; 37:1624–36. https://doi.org/10.1038/s41388-017-0057-3 PMID:29335523
33. Liu W, Kang L, Han J, Wang Y, Shen C, Yan Z, Tai Y, Zhao C. miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect. Onco Targets Ther. 2018; 11:1643–53. https://doi.org/10.2147/OTT.S161586
34. Chen Z, Zhuang W, Wang Z, Xiao W, Don W, Li X, Chen X. MicroRNA-450b-3p inhibits cell growth by targeting phosphoglycerate kinase 1 in hepatocellular carcinoma. J Cell Biochem. 2019; 120:18805–15. https://doi.org/10.1002/jcb.29196 PMID:3122833

35. Chen Z, Chen J, Liu H, Dong W, Huang X, Yang D, Hou J, Zhang X. The SMAC mimetic APG-1387 sensitizes immune-mediated cell apoptosis in hepatocellular carcinoma. Front Pharmacol. 2018; 9:1298. https://doi.org/10.3389/fphar.2018.01298 PMID:30459627

36. Chen Z, Xu G, Wu D, Wu S, Gong L, Li Z, Luo G, Hu J, Chen J, Huang X, Chen C, Jiang Z, Li X. Lobaplatin induces pyroptosis through regulating cIAP1/2, Ripoptosome and ROS in nasopharyngeal carcinoma. Biochem Pharmacol. 2020; 177:114023. https://doi.org/10.1016/j.bcp.2020.114023 PMID:32413426
### Supplementary Table

**Supplementary Table 1. Clinical features of 36 patients with HCC.**

| Variable                                           | Number/Mean±SD |
|----------------------------------------------------|----------------|
| Age (year)                                         | 52.61 ± 12.59  |
| Gender (male/female)                               | 32/4           |
| Family history of HCC (+/-)                        | 5/31           |
| History of drinking (+/-)                          | 6/30           |
| Cirrhosis (+/-)                                    | 27/9           |
| HBV DNA (≥<100 copies/ml)                         | 15/21          |
| HBsAg (+/-)                                        | 30/6           |
| HBsAb (+/-)                                        | 4/32           |
| HBcAb (+/-)                                        | 36/0           |
| HBeAg (+/-)                                        | 2/34           |
| HBeAb (+/-)                                        | 4/32           |
| alpha-Fetoproteins (>20/≤20 μg/L)                  | 18/18          |
| Alanine aminotransferase (>40/≤40 U/L)             | 15/21          |
| Aspartate aminotransferase (>40/≤40 U/L)           | 20/16          |
| Albumin (>35/≤35 g/L)                              | 22/14          |
| Total bilirubin (>17/≤17 μmol/L)                   | 14/22          |
| γ-glutamyl transpeptidase (>100/≤100 U/L)          | 27/9           |
| Tumor size (>3/≤3 cm)                              | 28/8           |
| Number of tumor nodules (>1/≤1)                    | 7/29           |
| Portal vein thrombus (+/-)                         | 5/31           |
| Distance metastasis (+/-)                          | 0/36           |
| Pathological differentiation (high/moderate/low)    | 1/15/20        |
| TNM stage (I/II/III/IIIa/IIIb)                     | 8/4/19/5       |

SD, standard deviation.